KRRO: Korro Bio, Inc. - Summary | Jitta

Korro Bio, Inc.

NASDAQ:KRRO

Price
$11.20
Loss Chance
57.9%
1.20JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
162 / 283
518 / 718
3,527 / 4,225
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (16)
Recent Business Performance (17)
Financial Strength (23)
Return to Shareholders (0)
Competitive Advantage (15)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Cash Conversion CycleLess than 60 days
Recent IPOLess than 3 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.20
100.00%
2.19
147.21%
3.05
202.32%
Biotechnology
5.68
35.90%
5.68
35.90%
4.58
55.04%
COMPANY DESCRIPTION
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.